Brief: Kezar Life Sciences To Present Complete Results From The Phase 2 Mission Trial Of Zetomipzomib At The American College Of Rheumatology Convergence 2022
29/09/2022 21:10
Sept 29 (Reuters) - Kezar Life Sciences Inc KZR.O :
* KEZAR LIFE SCIENCES TO PRESENT COMPLETE RESULTS FROM THE
PHASE 2
MISSION TRIAL OF ZETOMIPZOMIB IN PATIENTS WITH LUPUS NEPHRITIS
AT THE AMERICAN COLLEGE OF RHEUMATOLOGY CONVERGENCE 2022
Source text for Eikon: ID:nBw4pWpzXa
Further company coverage: KZR.O
Recent news on Kezar Life Sciences
See all newsNASDAQ TRADE HALT REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
U.S. STOCKS ON THE MOVE-Sysco, Crowdstrike, GM